BG
GTHX

Bellevue Group’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Bellevue Group’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-721,925
Closed -$8.34M – 228
2020
Q3 		$8.34M Hold
721,925
– – 0.12% 112
2020
Q2 		$17.5M Hold
721,925
– – 0.25% 85
2020
Q1 		$7.96M Hold
721,925
– – 0.15% 96
2019
Q4 		$19.1M Hold
721,925
– – 0.3% 63
2019
Q3 		$16.4M Buy
721,925
+50,000
+7% +$1.58M 0.31% 66
2019
Q2 		$20.6M Buy
+671,925
New +$14.1M 0.35% 57

Other funds holding GTHX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bellevue Group's GTHX Position: Q4 2020 in Review

Bellevue Group sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2020, closing a stake of 721,925 shares — an estimated $8.34M sold.

Bellevue Group first reported a position in GTHX in Q2 2019 and held it in 6 quarters. The position peaked at $20.6M in Q2 2019. 125 funds tracked by Wall St. Rank hold GTHX as of Q4 2020.

  • Bellevue Group reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Bellevue Group sold 721,925 G1 Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $8.34M.
  • Bellevue Group first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2019 and held it in 6 quarters.
  • Bellevue Group's G1 Therapeutics, Inc. Common Stock position peaked at $20.6M in Q2 2019.
  • 125 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Bellevue Group's 13F filing for Q4 2020, filed 16 Feb 2021.